A Aralex Aachen research explorer

Company ROR OpenAlex

Janssen (Netherlands) Sign in to save

550 stored papers · Search its papers → · Its authors →

Papers 550

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA
2020 Blood article Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes Open access

212

citations
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
2021 The Lancet Oncology article Medicine Multiple Myeloma Research and Treatments Open access

182

citations
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
2020 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access cited by 7 patents

173

citations
Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study
2020 European Respiratory Journal article Medicine Respiratory viral infections research Open access

168

citations
Stabilizing the closed SARS-CoV-2 spike trimer
2021 Nature Communications article Medicine SARS-CoV-2 and COVID-19 Research Open access cited by 7 patents

161

citations
Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination
2020 Science Translational Medicine article Medicine Malaria Research and Control cited by 2 patents

154

citations
Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults
2023 New England Journal of Medicine article Medicine Respiratory viral infections research Open access

153

citations
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
2020 medRxiv preprint Medicine SARS-CoV-2 and COVID-19 Research Open access

141

citations
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study
2024 Journal of Clinical Oncology article Medicine Lung Cancer Treatments and Mutations Open access cited by 3 patents

132

citations
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
2024 The Lancet Oncology article Medicine Multiple Myeloma Research and Treatments Open access

130

citations
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer
2021 New England Journal of Medicine article Medicine Heparin-Induced Thrombocytopenia and Thrombosis Open access

119

citations
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
2025 The Lancet Haematology article Medicine Multiple Myeloma Research and Treatments Open access

113

citations
Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years
2020 The Journal of Infectious Diseases article Medicine Respiratory viral infections research cited by 9 patents

111

citations
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
2021 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access cited by 2 patents

104

citations
Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques
2023 Nature article Medicine SARS-CoV-2 and COVID-19 Research Open access cited by 2 patents

104

citations
Geographic and Population Distributions of Human Immunodeficiency Virus (HIV)–1 and HIV-2 Circulating Subtypes: A Systematic Literature Review and Meta-analysis (2010–2021)
2023 The Journal of Infectious Diseases review Immunology and Microbiology HIV Research and Treatment Open access

97

citations
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
2021 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access

96

citations
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
2021 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access cited by 2 patents

94

citations
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial
2022 Nature Microbiology article Medicine SARS-CoV-2 and COVID-19 Research Open access

91

citations
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study
2020 The Lancet HIV article Immunology and Microbiology HIV Research and Treatment Open access cited by 3 patents

88

citations

Most cited authors